The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Staff Raises Safety Concerns Over Arthritis Drug Baricitinib

FDA Staff Raises Safety Concerns Over Arthritis Drug Baricitinib

April 26, 2018 • By Tamara Mathias

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—An experimental rheumatoid arthritis drug developed by Eli Lilly and Co. and Incyte Corp. poses serious risks of deadly blood clots at higher doses, U.S. Food and Drug Administration staff says, the latest setback to a treatment regulators declined to approve last year.

You Might Also Like
  • U.S. FDA Declines to Approve Eli Lilly & Incyte Arthritis Drug
  • Lilly’s Lupus Treatment Succeeds in Mid-Stage Trial
  • FDA Responds to New Drug Application for Baricitinib

New data provided by the companies in a resubmission of their marketing application did not substantially alter information from the original, the staffers note.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Shares of Lilly and Incyte were marginally down in early trading.

“At this point, approval in the U.S. is in jeopardy,” Hilliard Lyons analyst Kurt Kemper tells Reuters, adding that the review was much harsher than he had expected.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Safety data supported a lower 2 mg dose of the drug, baricitinib, but not a 4 mg dose, raising questions whether the higher dose provides additional benefit, the staffers say.

Also, the limited data available on the lower dose complicates the assessment of its risk/benefit analysis, the staffers add.

Evercore ISI analyst Josh Schimmer says questions over the doses could result in an awkward label for the drug.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Lilly and Incyte hope to launch baricitinib, a potential blockbuster, in the huge, competitive market for rheumatoid arthritis treatments, currently dominated by AbbVie’s Humira, the world’s top-selling prescription medicine.

Baricitinib is a once-daily pill that belongs to a class of drugs known as JAK inhibitors, which work by blocking inflammation-causing enzymes known as Janus kinases.

Ahead of Thursday’s assessment, experts were concerned that the review of baricitinib was likely to weigh on other companies with oral JAK inhibitors in their pipeline.

However, agency staffers noted that the risk of thrombosis, or blood clotting, appeared unique to baricitinib and had not been observed in other therapies, especially Pfizer Inc’s already approved Xeljanz.

“This could be a positive for competitors such as AbbVie and Gilead and Galapagos that have their own oral JAK inhibitors in late-stage development,” write Credit Suisse analysts.

The confusion over doses could also benefit AbbVie’s experimental drug upadacitinib, Evercore ISI’s Schimmer says.

All eyes are now on Monday’s advisory committee (Adcom) meeting when an independent panel of experts is scheduled to evaluate baricitinib based on data from the companies and the analysis by FDA staff.

The health regulator is not mandated to follow the panel’s recommendations, but usually does.

However, BMO Capital Markets analyst Alex Arfaei was not optimistic.

“We doubt the Adcom will alleviate the FDA’s safety concerns since they typically take a conservative approach, particularly when there is not a dire unmet need,” he writes in a note to clients.

Pages: 1 2 | Single Page

Filed Under: Drug Updates, Safety Tagged With: baricitinib, Drug Safety, FDA, Rheumatoid Arthritis (RA), U.S. Food and Drug Administration (FDA)

You Might Also Like:
  • U.S. FDA Declines to Approve Eli Lilly & Incyte Arthritis Drug
  • Lilly’s Lupus Treatment Succeeds in Mid-Stage Trial
  • FDA Responds to New Drug Application for Baricitinib
  • FDA Approves Baricitinib for RA Patients

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.